Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles.
Nat Commun
; 11(1): 1990, 2020 04 24.
Article
en En
| MEDLINE
| ID: mdl-32332749
Up-regulation of utrophin in muscles represents a promising therapeutic strategy for the treatment of Duchenne Muscular Dystrophy. We previously demonstrated that eEF1A2 associates with the 5'UTR of utrophin A to promote IRES-dependent translation. Here, we examine whether eEF1A2 directly regulates utrophin A expression and identify via an ELISA-based high-throughput screen, FDA-approved drugs that upregulate both eEF1A2 and utrophin A. Our results show that transient overexpression of eEF1A2 in mouse muscles causes an increase in IRES-mediated translation of utrophin A. Through the assessment of our screen, we reveal 7 classes of FDA-approved drugs that increase eEF1A2 and utrophin A protein levels. Treatment of mdx mice with the 2 top leads results in multiple improvements of the dystrophic phenotype. Here, we report that IRES-mediated translation of utrophin A via eEF1A2 is a critical mechanism of regulating utrophin A expression and reveal the potential of repurposed drugs for treating DMD via this pathway.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Biosíntesis de Proteínas
/
Distrofia Muscular de Duchenne
/
Factor 1 de Elongación Peptídica
/
Utrofina
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Idioma:
En
Revista:
Nat Commun
Año:
2020
Tipo del documento:
Article
País de afiliación:
Canadá